Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis - Wikidata - wikimedia - TriplyDB

Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis

Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis

http://www.wikidata.org/entity/Q26767418

about

Bacterial Pneumonia in Patients with Cancer: Novel Risk Factors and Management.Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma.

P2860

Q39287519-A89E87E6-E3BB-4C85-96BD-DA7819591919 Q50197484-50682A30-7EEB-424A-9B6F-EF281574CEEC

P2860

Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis

http://www.wikidata.org/entity/Q26767418

description

2016 nî lūn-bûn

@nan

2016 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis

@ast

Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis

@en

Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis

@nl

type

label

Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis

@ast

Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis

@en

Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis

@nl

prefLabel

Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis

@ast

Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis

@en

Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis

@nl

P1433

Q26767418-BA0E0341-6014-4290-9BE2-BF0A719B5C04

P1476

Q26767418-C29261C1-5F91-4197-9EDE-8A75C5C75BCF

P2093

Q26767418-26730AAC-5886-4599-AC23-198E5D748562

Q26767418-A3216494-9FBA-4498-80D2-71EF1067ACC0

Q26767418-C7BD7FF7-ADD7-400F-91CB-2740C1244CC9

P275

Q26767418-DCD6199B-CEC2-4917-A87D-F8EDAE0A5212

P2860

Q26767418-00E0F05C-0B96-4090-B347-272D9A158C1F

Q26767418-0A1A38E6-177E-4423-BDC4-B45B4029EA4F

Q26767418-0E0AD7DA-3420-438F-9656-98A5BFEACB85

Q26767418-1D50DD10-22BF-4215-BD14-79FE791422DD

Q26767418-28BDFF3B-F441-49EB-8180-A4CF3974FE23

Q26767418-3146AF23-8520-43A5-90CB-9FBA2D814B07

Q26767418-320496C6-DFAD-47D4-B4CF-6A91B5C16F61

Q26767418-3C322EEE-94EC-411F-82FB-4247107BB8A6

Q26767418-44570A03-C842-4490-B25B-3D842B9EBC42

Q26767418-480D556C-59BB-4E62-825B-3FEA5046A877

P304

Q26767418-804CDB43-A84B-44A2-AEB9-AEFA1891D83A

P31

Q26767418-00ADD6EB-2474-423D-953B-37F0DD05C62F

Q26767418-00F31A21-EA1E-4345-92D3-E92A2B1F588E

Q26767418-08169F04-531D-4203-A15E-01E0D5CC6CF0

P356

Q26767418-C5CA8829-B9CF-4A46-B47A-A37055BF6D26

P407

Q26767418-D1D90E10-40B2-4484-8218-20B67BE10DBA

P478

Q26767418-FBE84FEC-4E70-46C5-8BA0-F3775D3E3EC1

P5008

Q26767418-849DD941-FFA3-4A0E-B7D1-D2ADA3B051B6

P577

Q26767418-EE5A598E-123F-4C48-96BB-014F383D851C

P5875

Q26767418-5B6621CE-3AA2-4CE7-8A32-8D772507D870

P698

Q26767418-436EF5DE-1816-4628-B8CF-9BDCA2879FB5

P921

Q26767418-16138298-6F79-4DD8-8749-18A90472E5A1

Q26767418-60D6A494-224C-4537-8774-A4F3D49BE662

Q26767418-DE75CE90-F118-4C45-82C4-CF6FD8C4FA07

Q26767418-F89F445E-D1F9-4572-BE9F-EC4423E1F919

P932

Q26767418-18366EC0-209F-4B4E-BD0B-BBC562EBD780

P356

P1433

BioMed Research International

P1476

Efficacy and Safety of Novel Agent-Based Therapies for Multiple Myeloma: A Meta-Analysis

@en

P2093

Xiaojing Yan

http://www.w3.org/2001/XMLSchema#string

Xiaoxue Wang

http://www.w3.org/2001/XMLSchema#string

Yan Li

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

Practical methods for incorporating summary time-to-event data into meta-analysis

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system.

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.

Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women

P304

6848902

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2016/6848902

http://www.w3.org/2001/XMLSchema#string

P407

P478

2016

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2016-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

292678441

http://www.w3.org/2001/XMLSchema#string

P698

26949704

http://www.w3.org/2001/XMLSchema#string

P921

carboxylic acid

inorganic compound

heterocyclic compound

multiple myeloma

P932

4753325

http://www.w3.org/2001/XMLSchema#string